Theodora Caroline Harold
Chief Executive Officer at Crescendo Biologics Ltd.
Profile
Theodora Caroline Harold is currently the Chief Executive Officer at Crescendo Biologics Ltd.
She previously served as an Independent Non-Executive Director at Synairgen Plc from 2021 to 2022.
Additionally, she held positions at Akamis Bio Ltd., MISSION Therapeutics Ltd., Chronos Therapeutics Ltd., PricewaterhouseCoopers LLP, RioTech Pharmaceuticals Ltd., Cytomyx Holdings Plc, OrthoMimetics Ltd., and Hybrid BioSystems Ltd.
Theodora Caroline Harold active positions
Companies | Position | Start |
---|---|---|
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Chief Executive Officer | 2019-04-30 |
Former positions of Theodora Caroline Harold
Companies | Position | End |
---|---|---|
SYNAIRGEN PLC | Director/Board Member | 2022-09-28 |
Chronos Therapeutics Ltd.
Chronos Therapeutics Ltd. BiotechnologyHealth Technology Chronos Therapeutics Ltd. manufactures drugs. It pursuing innovative therapeutics for age-related diseases through the joint efforts of experts in medical research, drug discovery and business development. The company was founded in 2009 and is headquartered in Oxford, the United Kingdom. | Director/Board Member | - |
OrthoMimetics Ltd.
OrthoMimetics Ltd. Medical SpecialtiesHealth Technology Orthomimetics brings a new dimension to the treatment of joints damaged through sport or other orthopaedic trauma. Its heritage is a trans-Atlantic collaboration between two world-leading academic institutions, the University of Cambridge and the Massachusetts Institute of Technology (MIT), who have each contributed 30 years of experience to the repair of bone and soft tissues respectively. The harnessing of their expertise into viable therapeutic medical products is the foundation of Orthomimetics. | Corporate Officer/Principal | - |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Director of Finance/CFO | - |
PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Corporate Officer/Principal | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
SYNAIRGEN PLC | Health Technology |
Private companies | 9 |
---|---|
Cytomyx Holdings Plc
Cytomyx Holdings Plc Pharmaceuticals: MajorHealth Technology Cytomyx Holdings Plc provided drug discovery products and services. The company was founded in 1996 and was headquartered in Cambridge, the United Kingdom. | Health Technology |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
RioTech Pharmaceuticals Ltd.
RioTech Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology RioTech Pharmaceuticals Ltd. develops novel therapeutic drugs for hepatitis C virus. The company was founded on Nov 5, 2001 by Graham Foster, Adrian V. S. Hill, Peter Karayiannis, Howard David Thomas and Mark R. Thursz and is headquartered in Horsham, the United Kingdom. | Health Technology |
Hybrid BioSystems Ltd.
Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Hybrid is an Oxford Biotechnology Company focused on revolutionizing viral vaccines with its patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxford shire, which houses both its corporate research facility and contract research services. Using a mixed product and platform business model it is developing its in-house lead products towards phase I/II proof of concept clinical trials as well as furthering its partnerships with leading pharmaceutical and biotechnology companies. Hybrid's experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding. With its unparalleled expertise in the field of viral steal thing technologies, The firm is also able to offer general and bespoke virology services, including high-quality adenovirus production and purification. Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage. | Commercial Services |
PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
OrthoMimetics Ltd.
OrthoMimetics Ltd. Medical SpecialtiesHealth Technology Orthomimetics brings a new dimension to the treatment of joints damaged through sport or other orthopaedic trauma. Its heritage is a trans-Atlantic collaboration between two world-leading academic institutions, the University of Cambridge and the Massachusetts Institute of Technology (MIT), who have each contributed 30 years of experience to the repair of bone and soft tissues respectively. The harnessing of their expertise into viable therapeutic medical products is the foundation of Orthomimetics. | Health Technology |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Chronos Therapeutics Ltd.
Chronos Therapeutics Ltd. BiotechnologyHealth Technology Chronos Therapeutics Ltd. manufactures drugs. It pursuing innovative therapeutics for age-related diseases through the joint efforts of experts in medical research, drug discovery and business development. The company was founded in 2009 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
- Stock Market
- Insiders
- Theodora Caroline Harold